Clinical Trial Update: Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ecallantide for ACE inhibitor–induced angioedema was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ace Inhibitor-induced Angioedema

Drugs mentioned

• Ecallantide (ecallantide)

Snippet

Sponsor: Shire | Conditions: ACE Inhibitor Induced Angioedema | Phase 2 | Status: TERMINATED | Results posted: 2013-11-18